Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

BACKGROUND: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients. METHODS: Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacoki...

Descripción completa

Detalles Bibliográficos
Autores principales: Nabhan, C, Villines, D, Valdez, T V, Tolzien, K, Lestingi, T M, Bitran, J D, Christner, S M, Egorin, M J, Beumer, J H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419960/
https://www.ncbi.nlm.nih.gov/pubmed/22805325
http://dx.doi.org/10.1038/bjc.2012.312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419960/
https://www.ncbi.nlm.nih.gov/pubmed/22805325
http://dx.doi.org/10.1038/bjc.2012.312

Ejemplares similares